A discovery at Duke-NUS Medical School offers new hope in the battle against pulmonary fibrosis, a debilitating lung ...

Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline ...

An expert discusses the current understanding of corticosteroids in managing pulmonary fibrosis and how it has evolved in ...

Several weeks after reporting positive results for nerandomilast for idiopathic pulmonary fibrosis, Boehringer Ingelheim ...

Pliant Therapeutics has pumped the breaks on a mid-stage trial of its lead liver disease drug on the advice of its safety ...

Researchers from the European Molecular Biology Laboratory have found that dextromethorphan, a common cough syrup ingredient, ...

(NASDAQ:PLRX) stock is trading lower on Monday. On Friday, during after-hours trading, Pliant Therapeutics announced it has ...

A discovery at Duke-NUS Medical School offers new hope in the battle against pulmonary fibrosis, a debilitating lung condition that progressively makes it harder for patients to breathe. Scientists ...

Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...

The two positive studies mean that Boehringer can now seek approval for nerandomilast with a broad label claim in pulmonary ...

It is unclear why an independent data safety monitoring board recommended the suspension of Pliant’s Phase IIb/III BEACON-IPF ...

NEW YORK, NY / ACCESS Newswire / February 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pliant ...